Overview

SBRT Alone or Followed by Niraparib for Oligometastases or Oligoprogression in Ovarian Cancer Following PARPi Therapy

Status:
Not yet recruiting

Trial end date:
2027-06-30

Target enrollment:

Participant gender:

Summary

SOPRANO is a multi-centre, randomised phase II trial which aims to assess the impact of Stereotactic radiotherapy (SBRT) and continuing treatment with a PARP inhibitor (PARPi) for patients with oligometastatic or oligoprogressive ovarian, fallopian tube and primary peritoneal carcinoma. SOPRANO will also establish the feasibility and acceptability of delivering SBRT in this setting.

Phase:

Phase 2

Details

Lead Sponsor:

Institute of Cancer Research, United Kingdom

Collaborator:

Royal Marsden NHS Foundation Trust

Treatments:

Niraparib